ICH GCP Guidelines E6 Revision, R2 Addendum- Changes Impacting Sponsors-CRO-Sites by Compliance4All
WebcastFaculty
OVERVIEW
ICH GCP Guidelines E6 Revision, R2 Addendum- Changes Impacting Sponsors-CRO-Sites is organized by Compliance4All and will be held on Nov 06, 2018.
Overview:
Managing clinical trials, of any size and complexity, requires strategic planning and efficient execution. As scientific advances continue, the types of therapies being developed have higher potency and novel targets; and increased pressure to have study designs that speed up clinical development.
In 2016, the ICH revised the E6 guidelines to further standardize processes in biomedical products development, decrease redundancies; and reflect the current research landscape such as increases in globalization, study complexity, and technological capabilities. The revised guidelines are entitled "Integrated Addendum To ICH E6(R1): Guideline For Good Clinical Practice E6(R2)." The ICH steering committee comprised of representatives from the pharmaceutical industry and the regulatory bodies of the United States, Japan, the European Union (EU), Canada, and Switzerland.
In addition, observers include representatives from Brazil, China, South Korea, and the World Health Organization. The updated ICH GCP E6 R2 is more descriptive than the previous version and describes 26 items of change. These changes consist of new items in definitions; new sections on investigator responsibilities, including oversight; a substantial new sponsor section on quality management, including risk assessment; monitoring plans defined and implemented; introducing Risk-Based Quality Management; serious breaches, and, a new section on computer validation and electronic records, to name a few.
This session will explore the changes to provide a better understanding of how they impact conduct of clinical trials. Practical information and a systematic approach in assessing organizational SOPs, processes and practices as well as designing modifications to assist with implementation will also be provided.
Also, during this webinar we will evaluate solutions/applicability/modifications of organizational SOPs, processes, procedures and staff training; and discuss opportunities for implementing the revised guideline.
Why should you Attend:
In this webinar, we will identify the changes impacting investigators, sites, Sponsors, CROs: responsibilities and roles and explain the impact of the revisions on clinical trials conduct and organizational practices.
Areas Covered in the Session:
• GCP E6 R2 Guideline
• Globalization
• Risk-based Quality Management (RBQM)
• SOPs development and implementation, Standardization
Who Will Benefit:
• Directors of Clinical Operations
• Medical Affairs Specialists and Leaders of this Division
• Project Managers
• Grant Administrators
• Regulatory Affairs
• Quality Control(QC), Quality Assurance Specialists
Speaker Profile:
Dr. Malikova has over fourteen years of experience in the clinical research field. She has managed Phase I – IV studies involving investigational drugs, devices and biologics. She has worked on Industry-sponsored and Investigator-initiated trials in the fields of Surgery, Cancer Diagnostics and Interventional Radiology.
Event Fee: One Dial-in One Attendee Price: US $150.00
Overview:
Managing clinical trials, of any size and complexity, requires strategic planning and efficient execution. As scientific advances continue, the types of therapies being developed have higher potency and novel targets; and increased pressure to have study designs that speed up clinical development.
In 2016, the ICH revised the E6 guidelines to further standardize processes in biomedical products development, decrease redundancies; and reflect the current research landscape such as increases in globalization, study complexity, and technological capabilities. The revised guidelines are entitled "Integrated Addendum To ICH E6(R1): Guideline For Good Clinical Practice E6(R2)." The ICH steering committee comprised of representatives from the pharmaceutical industry and the regulatory bodies of the United States, Japan, the European Union (EU), Canada, and Switzerland.
In addition, observers include representatives from Brazil, China, South Korea, and the World Health Organization. The updated ICH GCP E6 R2 is more descriptive than the previous version and describes 26 items of change. These changes consist of new items in definitions; new sections on investigator responsibilities, including oversight; a substantial new sponsor section on quality management, including risk assessment; monitoring plans defined and implemented; introducing Risk-Based Quality Management; serious breaches, and, a new section on computer validation and electronic records, to name a few.
This session will explore the changes to provide a better understanding of how they impact conduct of clinical trials. Practical information and a systematic approach in assessing organizational SOPs, processes and practices as well as designing modifications to assist with implementation will also be provided.
Also, during this webinar we will evaluate solutions/applicability/modifications of organizational SOPs, processes, procedures and staff training; and discuss opportunities for implementing the revised guideline.
Why should you Attend:
In this webinar, we will identify the changes impacting investigators, sites, Sponsors, CROs: responsibilities and roles and explain the impact of the revisions on clinical trials conduct and organizational practices.
Areas Covered in the Session:
• GCP E6 R2 Guideline
• Globalization
• Risk-based Quality Management (RBQM)
• SOPs development and implementation, Standardization
Who Will Benefit:
• Directors of Clinical Operations
• Medical Affairs Specialists and Leaders of this Division
• Project Managers
• Grant Administrators
• Regulatory Affairs
• Quality Control(QC), Quality Assurance Specialists
Speaker Profile:
Dr. Malikova has over fourteen years of experience in the clinical research field. She has managed Phase I – IV studies involving investigational drugs, devices and biologics. She has worked on Industry-sponsored and Investigator-initiated trials in the fields of Surgery, Cancer Diagnostics and Interventional Radiology.
Event Fee: One Dial-in One Attendee Price: US $150.00
SPECIALITIES
Healthcare ManagementHealth InformaticsResearch and Clinical ResearchRELATED ONLINE COURSES
Quick Links